

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that, Shijiazhuang No.4 Pharmaceutical Company Limited (“Shijiazhuang No.4 Pharma”, a wholly owned subsidiary of the Company in China) has obtained the approval for drug production and registration for Prucalopride Succinate Tablets (1mg and 2mg) from the National Medical Products Administration. Shijiazhuang No.4 Pharma is one of first three enterprises in China that have passed the consistency evaluation and obtained such production approval under newly classified type 4 chemical drug. Prucalopride succinate is mainly used in treatment of chronic constipation symptoms.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
Company Secretary

Hong Kong, 22 July 2020

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*